Total
0
Shares
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon - The Market Herald
Managing Director, Fleta Solomon
Source: Little Green Pharma
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Little Green Pharma (LGP) has exported its first commercial shipment of cannabis flower medicines to Deutsche Medizinalcannabis
  • This is the first shipment in a three year-agreement between the companies
  • The shipment includes 500 units of cannabis flower medicines and is due to arrive in Germany next week
  • Upon arrival, the products will be batch-tested before being released to the German market
  • Notably, German medicinal cannabis market is anticipated to reach €7.7 billion (around A$12.22 billion) by 2028
  • LGP entered a trading halt this morning, ahead of an upcoming capital raise, and last traded at 93.5 cents per share

Little Green Pharma (LGP) has exported its first commercial shipment of cannabis flower medicines to Deutsche Medizinalcannabis (DEMECAN).

This first shipment includes 500 units of cannabis flower medicines and is due to arrive in Germany next week.

Upon arrival, the products will be batch-tested before being released to the German market.

This milestone follows a strict 12-month audit and qualification process between LGP and DEMECAN to ensure the product is applicable to European Union and German regulatory requirements.

"For the past year, we have worked closely with DEMECAN through a highly rigorous audit and qualification process, to ensure LGP’s cannabis flower medicines meet all applicable EU good manufacturing practice and German quality requirements," Managing Director Fleta Solomon said.

"In a particularly pleasing achievement, our cannabis flower medicines passed all
microbiological testing without requiring irradiation; a testament to LGP’s ability to successfully cultivate and manufacture consistently high-quality cannabis flower medicines under indoor GACP and GMP conditions," he added.

The medicines are being delivered under the purchase agreement between LGP and DEMECAN, which was signed in February 2020.

Under the agreement, LGP will sell and export up to 1000 kilograms of cannabis flower, or 48,000 units, to DEMECAN per annum.

Notably, Germany is the largest medicinal cannabis market in Europe and is anticipated to reach €7.7 billion (around A$12.22 billion) by 2028.

Earlier today, the company entered a trading halt as it prepares for a capital raise.

Prior to the trading halt, LGP shares traded at 93.5 cents each.

LGP by the numbers
More From The Market Herald
Imricor Medical Systems (ASX:IMR) - Chair and CEO, Steve Wedan - The Market Herald

" Imricor Medical Systems (ASX:IMR) signs agreement with MiRTLE Medical

Imricor Medical Systems (IMR) has signed an agreement with MiRTLE Medical for its 12-lead ECG system.
Telix Pharmaceuticals (ASX:TLX) - CFO, Doug Cubbin - The Market Herald

" Telix Pharmaceuticals (ASX:TLX) bags $12.1m R&D tax refund, increases overseas finding to $139m

Telix Pharmaceuticals (TLX) has pocketed a research and development (R&D) tax refund of $12.1 million for eligible activities undertaken in the 2020 calenda…
Mach7 Technologies (ASX:M7T) - CEO, Mike Lampron - The Market Herald

" Mach7 (ASX:M7T) provides PACS Solution to Trinity Health in US

Mach7 Technologies (M7T) has received purchase orders for its software and services from Trinity Health totalling $3.6 million.
Pfizer tests new antiviral pill

" Pfizer tests new antiviral pill

Major vaccine producer Pfizer says it will start trials for an antiviral pill for those who have been exposed to COVID-19.